Elevated doses of carmustine and mitomycin C, with lonidamine enhancement and autologous bone marrow transplantation in the treatment of advanced colorectal cancer: results from a pilot study

• Published in: European journal of cancer (1990) Vol. 30A; no. 10; pp. 1420 - 1423
• Main Authors: Franchi, F, Seminara, P, Codacci Pisanelli, G, Guazzugli Bonaiuti, V P, Giovagnorio, F, Gualdi, G
• Format: Journal Article
• Language: English
• Published: England 1994
• Subjects: Adult; Antineoplastic Agents - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Marrow Transplantation; Carmustine - administration & dosage; Colonic Neoplasms - drug therapy; Colonic Neoplasms - mortality; Colonic Neoplasms - therapy; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Indazoles - administration & dosage; Male; Middle Aged; Mitomycin - administration & dosage; Pilot Projects; Rectal Neoplasms - drug therapy; Rectal Neoplasms - mortality; Rectal Neoplasms - therapy; Survival Analysis
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(93)E0161-I

10 patients with advanced colorectal cancer were treated with elevated doses of carmustine and mitomycin C. The regimen was potentiated by lonidamine and supported by autologous bone marrow transplantation. The results of this pilot study were encouraging, with a response rate of 50% and a significantly better survival for responders versus non-responders. No appreciable toxicity of the therapy was observed. This aspect, together with the simplicity of the procedure, calls for further investigations to confirm the good therapeutic index of the treatment.